Intel: Priced for a foundry turnaround years before the earnings show up

Stevie AI on Intel Corporation (INTC-USA | intelcorpora)

10/27/2026

Summary

Intel is in the middle of the most expensive and highest-stakes transformation in its history, attempting to simultaneously defend its x86 franchise in CCPG and DCAI while standing up Intel Foundry Services as a credible external alternative to TSMC. The structural insight is simple: the market is capitalizing the company as though the 18A/14A node transition and foundry customer wins are a foregone conclusion, when the financial evidence to date shows a company still generating near-zero net income on $53B of revenue after two consecutive years of essentially flat top line. The stock at $90.47 embeds a valuation that is disconnected from the depressed earnings power the forecast actually implies through at least 2028. The historical actuals are sobering: FY2024 revenue of $53.1B produced a net loss of $18.8B (EPS -$4.38), and FY2025 revenue of $52.9B essentially broke even at -$0.3B net income (EPS -$0.06). Two years of flat-to-declining revenue alongside a multi-tens-of-billions capex program is not the profile of a company that should command a premium multiple. The forecast path shows only gradual improvement — $1.0B net income in FY2026, rising to $5.4B by FY2029 — while free cash flow remains negative every single year of the forecast horizon (-$10.0B in FY2026 widening to -$12.5B in FY2027 before narrowing to -$3.5B by FY2029), and net debt nearly doubles from $41.5B to $65.0B over the period as the U.S.-centric capex program (>$20B in 2026, stepping up further in 2027) consumes cash faster than the business generates it. Applying a 20x forward P/E to the first clearly profitable forecast year (FY2027 EPS of $0.52) — a multiple that reflects Intel's position as a structurally challenged, capital-intensive, low-margin semiconductor manufacturer rather than a growth compounder — yields a FY2027 target of roughly $10.40, discounted back to $9.45 for FY2026 given its near-breakeven EPS. Rolling forward, FY2028 EPS of $0.86 supports a target near $17.20, and FY2029 EPS of $1.11 supports approximately $22.20. Every one of these targets sits dramatically below the current $90.47 price, implying the stock is pricing in an earnings recovery and foundry validation that the base-case forecast simply does not support for years, if ever.

Thesis

1. **Foundry optionality is real but years from monetization.** Intel's IDM 2.0 bet — combining internal design, advanced packaging (EMIB-T), and wafer production — is a genuinely differentiated strategic position among Western semiconductor companies, and 14A risk production in H2 2027 with high-volume ramp in 2028 represents a credible technical roadmap. But credible roadmap and monetized external customer revenue are different things. The forecast itself only gets IFS to breakeven-adjacent economics by the tail end of the period, and management has not disclosed a single marquee external foundry customer commitment of scale. The PDK 0.9 delivery in October 2026 is a milestone, not a revenue event. 2. **Revenue growth is structurally capped through 2027.** The forecast shows revenue growing from $53.9B in FY2026 to just $60.9B in FY2029 — a compound growth rate in the low-single digits. This is happening against a backdrop of AMD taking server and client share with competitive process nodes and pricing, and Nvidia controlling the AI accelerator market that is driving the bulk of data center capex growth industry-wide. Intel's Granite Rapids strength and Panther Lake ramp are real but are fighting for share in a market where the fastest-growing segment (AI accelerators) is one Intel barely participates in. 3. **The capex-to-FCF math does not support current leverage.** Capex is rising above $20B in 2026 and 'significantly above' that in 2027, while free cash flow stays negative every year through the forecast horizon and net debt climbs from $41.5B to $65.0B. This is capital intensity without commensurate near-term return — Intel is being asked to fund a generational manufacturing buildout (U.S. capex approaching $100B gross 2021-2026) from a balance sheet that is simultaneously trying to recover from two years of net losses. Noncontrolling interest contributions (~$250M/quarter 2026, ~$1.1B 2027-2028) and ITC credits help at the margin but do not change the fundamental cash burn trajectory. 4. **Margin recovery is gradual and contingent on execution Intel has repeatedly struggled with.** Non-GAAP gross margin guidance of 42% for Q3 2026 sounds constructive, but the GAAP picture is muddied by heavier depreciation from the elevated capex program. The narrative explicitly describes margins improving 'slowly' from the mid-30s toward high-30s/low-40s — this is a multi-year grind, not an inflection. Opex discipline (~$16.5B target for 2026) is necessary but not sufficient to drive the kind of operating leverage that would justify a re-rating at current prices. 5. **The market is mispricing the gap between narrative and numbers.** At $90.47, Intel trades as though the foundry and node transition thesis has already been proven out, yet the consensus-aligned forecast shows EPS of just $0.21 in FY2026 and $1.11 even by FY2029 — a trajectory that, even generously multiplied, supports a fraction of the current share price. This disconnect likely reflects optimism around strategic significance (U.S. national security angle, CHIPS Act-adjacent support, potential government or large-customer backstops) rather than any near-term earnings reality. Sentiment-driven re-ratings on node or customer-win headlines are a real risk to a short thesis, but they do not change the underlying cash generation profile. 6. **Catalysts over the next 12 months are more likely to disappoint than surprise positively.** Q3 2026 earnings (October 29, 2026) will update 2027 capex guidance, which management has already signaled will step up 'significantly' — a negative FCF catalyst, not a positive one. The 14A PDK delivery is a technical checkpoint with limited near-term revenue read-through. Absent an announced large external foundry customer, the catalyst calendar skews toward confirming the capital intensity problem rather than resolving it.

Risks

1. **External foundry customer win announcement.** A marquee external customer commitment (particularly at 18A or 14A) could re-rate the stock meaningfully higher by validating the IDM 2.0 thesis years ahead of what the base case assumes, directly invalidating the bearish framing of this view. 2. **U.S. government and policy support.** Given the national security dimension of domestic semiconductor manufacturing, additional government support (CHIPS Act follow-ons, defense procurement, equity stakes, or tariff protection against TSMC/Samsung) could alter the capex funding equation and reduce balance sheet risk in ways not captured in the base financial forecast. 3. **Memory, substrate, and back-end supply constraints.** Management has explicitly flagged memory and substrate as the most challenged parts of the supply chain, with EMIB-T backlog growing but yield and scale-up unproven. Any external packaging disruption could constrain revenue upside precisely when Panther Lake and Granite Rapids are supposed to be driving the recovery narrative — a risk that cuts against both bull and bear cases depending on severity. 4. **14A execution risk cuts both ways.** If 14A risk production (H2 2027) and the 2028 high-volume ramp go well, this removes the single biggest overhang on the foundry thesis and could justify a higher multiple than the 20x applied here. Conversely, any further node delay (following a well-documented history of such delays at Intel) would push profitability recovery out further and make even the depressed price targets in this note optimistic. 5. **Macro capex and labor market softness capping volumes.** The forecast already assumes a soft macro backdrop through 2027, but a sharper enterprise capex pullback or PC/server demand air pocket could push the modest revenue growth assumed (low-to-mid single digits) into outright decline, pressuring the already thin profitability path further. 6. **Balance sheet and dilution risk.** Net debt rising from $41.5B to $65.0B over the forecast period, combined with a capital program that keeps FCF negative every year through 2029, raises the possibility of further equity raises, asset sales, or JV structures (beyond the NCI arrangements already disclosed) that could dilute existing shareholders or change the per-share earnings trajectory materially from what is modeled here.

📈 Price Targets